Invention Grant
US08664184B2 Therapy with Clostridium perfringens enterotoxin to treat ovarian and uterine cancer 有权
用产气荚膜梭菌肠毒素治疗卵巢癌和子宫癌

  • Patent Title: Therapy with Clostridium perfringens enterotoxin to treat ovarian and uterine cancer
  • Patent Title (中): 用产气荚膜梭菌肠毒素治疗卵巢癌和子宫癌
  • Application No.: US13250380
    Application Date: 2011-09-30
  • Publication No.: US08664184B2
    Publication Date: 2014-03-04
  • Inventor: Alessandro D. Santin
  • Applicant: Alessandro D. Santin
  • Applicant Address: US CT New Haven
  • Assignee: Yale University
  • Current Assignee: Yale University
  • Current Assignee Address: US CT New Haven
  • Agent Henry D. Coleman; R. Neil Sudol
  • Main IPC: A61K38/00
  • IPC: A61K38/00
Therapy with Clostridium perfringens enterotoxin to treat ovarian and uterine cancer
Abstract:
The invention discloses high levels of receptors for Clostridium perfringens enterotoxin (CPE) have been found in ovarian cancer and uterine cancer tissue samples. In addition, successful in vivo treatment of a mouse model of ovarian cancer with intraperitoneal injection of CPE is disclosed. High levels of Ep-CAM protein is also disclosed in ovarian cancer tissue samples. Thus, the invention provides a method of treating ovarian cancer and uterine cancer by administering CPE. The invention also provides a method of treating cancer in a mammal involving intraperitoneal administration of CPE, where at least some cancerous cells are located in or adjacent to the peritoneal cavity of the mammal. The invention also provides a method of treating ovarian cancer involving administering an anti-Ep-CAM antibody. The invention also provides a method of treating cancers expressing claudin-3 or claudin-4 by administering an antibody against claudin-3 and/or an antibody against claudin-4. The invention also provides a method of protecting a mammal from CPE toxicity involving administering a protective agent that binds to claudin-3 and/or claudin-4 and inhibits CPE binding to claudin-3 and/or claudin-4.
Information query
Patent Agency Ranking
0/0